M2 Presswire - Sales of Abarelix for the Treatment of Prostate Cancer was Forecasted to Reach $450 million.
January 15, 2007 -- M2 PRESSWIRE-15 January 2007-Research and Markets: Sales of Abarelix for the Treatment of Prostate Cancer was Forecasted to Reach $450...
Business Wire - Research and Markets : Sales of Abarelix For the Treatment of Prostate Cancer Was Forecasted to Reach $450 million
January 15, 2007 -- DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c48492) has announced the addition of Prostate Cancer - A...
Business Wire - There Are Currently No Less Than 220 Emerging Therapeutics Targeting Prostate Cancer, from Early Preclinical to Marketed Drugs
January 15, 2007 -- DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c48450) has announced the addition of the new Bioseeker report...
Business Wire - ON24 Audio Investor Alert: Amgen VP: Highly Competitive Market Awaits Abarelix
June 5, 2001 -- Business Editors & Analysts --(BUSINESS WIRE) Amgen Vice President of the Urology Unit is hopeful for Abarelix by the end of the year. For the...
Business Wire - PRAECIS PHARMACEUTICALS INCORPORATED Announces German Regulatory Approval for Plenaxis®; Schering AG Collaboration Terminated
September 29, 2005 -- WALTHAM, Mass. -- PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced that it has received marketing authorization for Plenaxis(R)...
Business Wire - PRAECIS PHARMACEUTICALS INCORPORATED Announces Issuance of Final National Coverage Determination for Plenaxis
March 16, 2005 -- WALTHAM, Mass. -- PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced that the Centers for Medicare and Medicaid Services (CMS) has...
Business Wire - PRAECIS PHARMACEUTICALS INCORPORATED Provides Update on Direct Select Technology at Molecular Medicine Tri-Conference
April 19, 2005 -- WALTHAM, Mass. -- PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced that it will present an update on the development of its Direct...
Business Wire - PRAECIS PHARMACEUTICALS INCORPORATED Announces Issuance of Draft National Coverage Determination for Plenaxis
December 20, 2004 -- WALTHAM, Mass. -- PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS), today announced that the Centers for Medicare and Medicaid Services (CMS) has...
Business Wire - PRAECIS PHARMACEUTICALS INCORPORATED Provides Update on Plenaxis Commercialization
December 6, 2004 -- WALTHAM, Mass. -- PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS), today provided an update on the Company's commercialization of Plenaxis(R)...
Business Wire - PRAECIS PHARMACEUTICALS INCORPORATED Reports Third Quarter 2004 Financial Results and Provides Update on Plenaxis Commercialization and Clinical Development...
October 29, 2004 -- WALTHAM, Mass. -- PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced consolidated financial results for the three and nine months...
